颖泰生物(833819) - 2023 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders in the range of 90 million to 110 million CNY, representing a decrease of approximately 89.59% to 91.48% compared to the same period last year, where the profit was 1,056.89 million CNY[4]. - The decline in performance is attributed to factors such as a slowdown in downstream customer demand, industry destocking, and intensified market competition[5]. - The company's market sales scale has contracted, and product profitability has decreased year-on-year due to the adverse market conditions[6]. - The financial data presented is preliminary and has not been audited, with the final figures to be disclosed in the annual report[2][7].